

HUNTON & WILLIAMS

1900 K STREET, N.W.

WASHINGTON, D.C. 20006-1109

TELEPHONE (202) 955-1500

FACSIMILE (202) 778-2201

BRUSSELS, BELGIUM
WARSAW, POLAND
HONG KONG, CHINA
BANGKOK, THAILAND
NEW YORK, NEW YORK
ATLANTA, GEORGIA

ANISLAUS AKSMAN*

E-MAIL: SAKSMAN@HUNTON.COM

Admitted to Virginia Bar Only

RICHMOND, VIRGINIA
MCLEAN, VIRGINIA
NORFOLK, VIRGINIA
RALEIGH, NORTH CAROLINA
CHARLOTTE, NORTH CAROLINA
KNOXVILLE, TENNESSEE

FILE NO.: 54259.000003

DIRECT DIAL: (202) 955-1926

April 29, 1999

VIA HAND DELIVERY

Honorable Commissioner
of Patents and Trademarks
Washington, DC 20231

Re: U.S. Utility Patent Application
For: NOVEL MULTIFUNCTIONAL ADHESIN PROTEINS
AND THEIR DISPLAY IN MICROBIAL CELLS
Applicants: Mark Andrew SCHEMBRI, *et al.*
Based On: Provisional Application Serial Number 60/083,794
Filed May 1, 1998
Our Reference: 54259.000003

Dear Sirs:

Transmitted herewith for filing in the U.S. Patent and Trademark Office is a patent application of Mark Andrew SCHEMBRI, *et al.* entitled "Novel Multifunctional Adhesin Proteins And Their Display In Microbial Cells." The application includes forty-three (43) pages of specification, four (4) pages of claims (numbered 1-32), one (1) page of Abstract, and eight (8) pages of figures (Figs. 1-8).

Applicants claim the benefit of priority under 35 U.S.C. § 119(e) of U.S. Provisional Application Serial Number 60/083,794, filed May 1, 1998, entitled Novel Multifunctional Adhesin Proteins And Their Display In Microbial Cells, and the benefit of priority under 35 U.S.C. § 119(a)-(d) of application Serial No. PA 1998 00598, filed on April 30, 1998 in Denmark.

HUNTON & WILLIAMS

Honorable Commissioner
of Patents and Trademarks
April 29, 1999
Page 2

The filing fee is calculated as follows and is based on the claims included in this application and the enclosed Preliminary Amendment:

Basic Filing Fee	\$ 760.00
Total Claims: 61	
Independent Claims (2)	\$ 0
Dependent Claims (59)	
(41 claims in excess of 20)	\$ 738.00
Multiple Dependency Claim Fee	\$ <u>260 00</u>
Total Filing Fee:	\$1,788.00

Also enclosed are:

1. Preliminary Amendment;
2. Submission of Sequence Listing and Statement Under 37 C.F.R. § 1.821; and
3. Information Disclosure Statement, PTO-1449 with 20 references.

The Applicants are:

Mark Andrew Schembri
c/o Anni Nihm
Lilletoften 102, 3. tv.
2740 Skovlunde
DENMARK

Per Klemm
Stokkevad 1
2850 Naerum
DENMARK

A check in the amount of \$1,788.00 is attached to cover the required fees. In the event of any variance between the amount enclosed and the Patent Office charges, please charge or credit any difference to the undersigned's Deposit Account No. 50-0206.

HUNTON & WILLIAMS


Honorable Commissioner
of Patents and Trademarks
April 29, 1999
Page 3

Please direct all communication concerning this application to:

Stanislaus Aksman, Esq.
Hunton & Williams
1900 K Street, N.W., Suite 1200
Washington, DC 20006

Respectfully submitted,

HUNTON & WILLIAMS

By: 
Stanislaus Aksman
Registration No. 28,562

SA/ts

Enclosures

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of :)
Mark Andrew SCHEMBRI, *et al.*) Group Art Unit: To Be Assigned
Serial No.: To be Assigned) Examiner: To Be Assigned
Filed: Herewith)
For: NOVEL MULTIFUNCTIONAL ADHESIN PROTEINS AND THEIR
DISPLAY IN MICROBIAL CELLS

PRELIMINARY AMENDMENT

Honorable Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

Prior to the examination of the above-identified patent application, please amend
the application as follows:

IN THE CLAIMS

Claim 2, line 1, change "claim 2" to - - claim 1 - -;

Claim 16, line 2, change "claims 1-15" to - - claim 1 - -;

Claim 28, line 1, change "claims 1-15" to - - claim 1 - -;

Claim 31, line 1, change "claims 1-15" to - - claim 1 - -.

Applicants amended dependency of selected claims.

An indication of allowance to all claims is solicited


In the event any fees are due, the Commissioner is hereby authorized to charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS

Date: April 29, 1999

By:


Stanislaus Aksman
Registration No. 28,562

1900 K Street, N.W., Suite 1200
Washington, D.C. 20006-1109
Telephone: (202) 955-1500
Facsimile: (202) 778-2201

U.S. PATENT & TRADEMARK OFFICE
WASHINGTON, D.C. 20503
TELEPHONE (202) 279-2000
FACSIMILE (202) 279-2000
WWW.USPTO.GOV

NOVEL MULTIFUNCTIONAL ADHESIN PROTEINS AND THEIR DISPLAY IN MICROBIAL CELLS

5 FIELD OF THE INVENTION

The present invention relates to microbial cells that express surface structures comprising adhesin proteins having the capability to bind to at least two different target molecules (heterobinary adhesins). Specifically there is provided cells that
10 express a library of genes encoding modified FimH adhesins, and an enrichment procedure permitting the isolation of cells expressing adhesins binding preferentially to selected target molecules including metal compounds.

15 TECHNICAL BACKGROUND AND PRIOR ART

The ability of microorganisms to adhere or bind specifically to and to colonize animate or inanimate surfaces is of paramount importance in microbial ecology and pathogenesis. Such specific receptor binding is provided by adhesin proteins which
20 play a key role in bacterial/host and viral/host recognition and interaction and for the recognition of any specific surface by a microorganism.

Accordingly, adhesion of bacteria to target surfaces is commonly regarded as an essential step enabling bacteria to become established as members of the normal flora
25 of such surfaces. Bacterial lectins are the most common and most thoroughly studied types of adhesins among both gram-negative and gram-positive bacteria.

One class of structures that a large range of gram-positive and gram-negative bacteria including *Escherichia coli* and other members of the family *Enterobacteriaceae* have
30 evolved to adhere to glycoprotein receptors in a saccharide-dependent manner are surface fibrils called fimbriae or pili. By far the most common of the enterobacterial fimbriae is type 1, or mannose-specific (MS) fimbriae which are heteropolymers of four different subunits.

A single type 1 fimbriae is a 7 nm wide and approximately 1 μ m long heteropolymer. It consists of approximately 1000 subunits of the major building element, FimA, polymerized into a right-handed helical structure also containing a few percent of the minor components FimF, FimG and FimH (Klemm et al., 1987). The FimH protein has
 5 been shown to be the actual receptor-binding molecule which recognises α -D-mannose-containing structures (Krogfelt and Klemm, 1988). By virtue of this type 1 fimbriae bacteria readily agglutinate yeast cells (a rich source of mannan).

The FimH adhesin is located at the fimbrial tip and also interspersed along the fimbrial
 10 shaft (Jones et al., 1995). Linker insertion mutagenesis (Schembri et al., 1996), analyses of naturally occurring variants (Sokurenko et al., 1992 and 1995) and hybrid proteins constructed by fusions to FocH (Knudsen and Klemm, 1998) and MalE (Thankavel et al., 1997) suggest that the FimH protein consists of two major domains, each constituting roughly one half of the molecule; the N-terminal domain seems to
 15 contain the receptor binding site, while the C-terminal domain seems to contain the recognition sequences for export and bioassembly.

Expression systems for the display of heterologous protein segments have facilitated the presentation of both defined and random peptide sequences at exposed regions in
 20 surface proteins of filamentous bacteriophage virions, bacteria and yeast (Sousa et al., 1996; Boder et al., 1997; Georgiou et al., 1997.)

The ability of FimH to display heterologous peptides in connection with the development of vaccine systems has been disclosed in WO 95/20657 where it was
 25 shown that various heterologous sequences, representing immune-relevant fragments of foreign proteins, can be authentically displayed on the bacterial surface in FimH.

It has now been found that the FimH adhesin protein is an ideal candidate for the display of random peptide sequences without affecting the inherent receptor binding
 30 characteristics of the adhesin. Thus, by inserting in an adhesin protein peptide sequences having the capability to bind to further target molecules, the invention opens up for the possibility to construct what can be referred to as designer adhesins, i.e. adhesin proteins manipulated to bind to specific pre-selected targets including simultaneous multifunctional target binding of recombinant cells expressing chimeric

fimbrial adhesin proteins or such isolated fimbriae, which are not only capable of binding to the normal target for the adhesin but also to other targets to which the adhesin does not normally bind.

5

SUMMARY OF THE INVENTION

Accordingly, the invention relates in a first aspect to a recombinant cell expressing on its surface a multifunctional adhesin protein derived from a naturally occurring adhesin protein, the multifunctional adhesin protein containing at least one first kind of binding domain and at least one second kind of binding domain, said first kind of binding domain is capable of binding to an organic receptor and said second kind of binding domain is one that is not naturally present in the adhesin protein from which the multifunctional adhesin protein is derived and is capable of binding to a compound to which the naturally occurring adhesin protein substantially does not bind.

In a further aspect the invention provides a method of removing a metal compound from an environment, comprising adding to said environment a cell as defined above which is capable of binding the metal compound to the second kind of binding domain, and separating the cell from the environment.

There is also provided a population of recombinant cells, the population comprising a multiplicity of clones of a cell as defined above, each of which clones expresses an adhesin comprising a different second kind of binding domain.

25

In a still further aspect, the invention relates to a method of constructing such a cell population, the method comprising the steps of constructing a random library of DNA sequences coding for a peptide, inserting the library into a gene coding for an adhesin protein, and transforming a host cell population with the library.

30

In other aspects the invention relates to an isolated fimbrial structure comprising a multifunctional adhesin protein that contains at least one first kind of binding domain and at least one second kind of binding domain, said first kind of binding domain is capable of binding to an organic receptor and said second kind of binding domain is

- capable of binding to a compound to which the naturally occurring adhesin protein substantially does not bind and to the use of a cell or a fimbrial structure as defined above for removing a compound from an environment, the method comprising adding to the environment said cell or said fimbrial structure, which is capable of binding the
- 5 compound to the second kind of binding domain and separating aggregates of cell or fimbrial structure with the compound from the environment.

DETAILED DISCLOSURE OF THE INVENTION

10

One major objective of the invention is to provide a recombinant cell expressing a multifunctional adhesin protein on its surface. As used herein the term "adhesin protein" denotes proteins which inherently recognise and bind to a large variety of target molecules such as polysaccharides, glycolipids, glycoproteins, polypeptides or

- 15 proteins. More than a hundred different adhesins have been described so far originating from a large variety of gram-negative and gram-positive bacteria. Adhesins can be present on the bacterial surface as components of organelles such as fimbriae, also called pili or fibrillae, these three terms being used interchangeably herein, or as non-fimbrial or afimbrial adhesins. Examples of fimbrial or pili adhesins include the
- 20 following surface structures in *E. coli*: P pili, type 1 fimbriae, S pili, K88 pili, K99 pili, CS3 pili, F17 pili and CS31 A; in *Klebsiella pneumoniae*: type 3 pili; in *Bordetella pertussis*: type 2 and 2 pili; in *Yersinia enterocolitica*: Myf fibrillae; in *Yersinia pestis*: pH6 antigen and F1 envelope antigen.

- 25 Examples of non-fimbrial cell surface structures which have adhesin function or which may comprise proteins having such a function include capsules, lipopolysaccharide layers, outer membrane proteins, NFA (non-fimbrial adhesin) -1, NFA-2, NFA-3, NFA-4, AFA (afimbrial adhesins) -I, AFA-II and AFA-III.

- 30 In the present context, the term "fimbriae" designates long thread-like bacterial surface organelles. Fimbriae are heteropolymers each consisting of about 1000 structural components, mostly of a single protein species. However, in many cases a few percent minor components are also present. Adhesins can either be identical to the major structural protein as in *Escherichia coli* K88 and CFA fimbriae and type 4

fimbriae of *Pseudomonas*, *Vibrio* and *Neisseria*, or they may be present as minor components as in *E. coli* type 1 and P fimbriae. In the latter case the adhesins are closely related in amino acid sequence to the major fimbrial component. As used herein the term bacterial adhesin will also include adhesins isolated from non-bacterial sources including viruses, and which is expressed in a bacterium. In the following the FimH adhesin of type 1 fimbriae will be used and described as a representative example of microbially derived adhesins.

The *fimH* gene encodes the precursor FimH protein of 300 amino acids (Klemm et al., 1987). Three *fim* genes are required for the regulation of length and mediation of adhesion of *Escherichia coli* type 1 fimbriae. This precursor is processed into a mature form of 279 amino acids. The amino acid sequence of the *E. coli* PC31 FimH protein is shown in Table 1 below wherein cysteine residues are indicated by asterixes, the signal peptide is outlined in bold letters, and the two regions contributing to the binding site are underlined. (It should be noted that residue 176 is a proline residue and not as previously indicated when the PC31 FimH protein was first published, an arginine residue):

Table 1. Amino acid sequence of the *E. coli* PC31 FimH protein (SEQ ID NO:1)

```

-21              1 *
MKRVITLFAVLLMGWSVNAWSFACKTANGTAIPIGGGSANVYVNLAPVVNVGQNLVVDLS
*
25 TQIFCHNDYPETITDYVTLQRGSAYGGVLSNFSGTVKYSGSSYPFPTTSETPRVVYNSRT

DKPWPVALYLTPVSSAGGVAIKAGSLIAVLILRQTNNYNSDDFQFVWNIYANNDVVVPTG
*              *

GCDVSARDVTVTLPDYPGSVPIPLTVYCAKSQNLGYLSGTHADAGNSIFTNTASFSPAQ
30                                     279
GVGVQLTRNGTIIPANNTVSLGAVGTSAVSLGLTANYARTGGQVTAGNVQSIIGVTFVYQ

```

The FimH contains 4 cysteine residues assumed to direct folding of the molecule into distinct functional domains. The localisation of the cysteine residues in FimH points to

a tandem arrangement of two ancestral genes. Furthermore, similar amino acids can be found in similar positions in the two halves of the FimH protein. The "midway" point is located roughly around residue 150 in the mature protein. The two halves or domains of FimH have evolved differently with the N-terminal section becoming the
 5 domain harbouring the receptor binding site, whereas the C-terminal sector became the domain of the molecule required for integration into the fimbrial organelle structure, i.e. having the features of a structural component.

In accordance with the invention, the microbial cell that expresses the multifunctional
 10 adhesin protein can be selected from any prokaryotic or eukaryotic cells that are capable of expressing an adhesin protein on their surface. Such cells include gram-negative bacterial cells such as *Enterobacteriaceae* and *Pseudomonadaceae*, gram-positive bacterial cells, fungal cells including yeast cells, animal cells including human cells and insect cells, and plant cells.

15 In the present context, the expression "multifunctional adhesin protein" refers to a cell surface structure as defined above that, in addition to a naturally occurring binding domain, comprises at least one further binding domain that does not naturally occur in the particular adhesin protein. This at least one further domain confers to the cell the
 20 ability to bind to a target molecule to which the cell does not normally bind.

Thus, the multifunctional adhesin is derived from a naturally occurring adhesin protein inherently having a first kind of binding domain which is capable of binding to an organic receptor and which is modified to contain at least one second kind of binding
 25 domain that is one not naturally present in the adhesin protein from which the multifunctional adhesin protein is derived and which is capable of binding to a compound to which the naturally occurring adhesin protein substantially does not bind.

30 Although it may, in certain embodiments, be preferred that the first kind of binding domain is a naturally occurring binding domain, it is within the scope of the invention to provide a microbial cell according to the invention that expresses an adhesin protein where the first kind of binding domain has an amino acid sequence which differs from that of the naturally occurring binding domain and which thereby has acquired the

ability to bind to receptor molecules to which the adhesin does not bind naturally. In one specific embodiment, the microbial cell expresses an adhesin protein where the first kind of binding domain has an amino acid sequence which differs from the *E. coli* PC31 FimH adhesin as defined above in at least one amino acid, including in at least
 5 three amino acids, whereby its inherent saccharide binding characteristics is changed relative to those of the naturally occurring *E. coli* PC31 FimH adhesin.

In a presently preferred embodiment, the second kind of binding domain is provided in the adhesin protein by inserting into the gene coding for the selected adhesin protein a
 10 DNA sequence coding for a peptide sequence conferring the capability of binding to a compound to which the naturally occurring adhesin protein substantially does not bind, whereby the adhesin is expressed as a chimeric protein comprising said first and second kind of binding domains. It will be appreciated that the insertion of such an additional DNA sequence preferably should be at a site where the binding function of
 15 the first kind of binding domain is substantially not affected. The insertion of the DNA sequence can be carried out using any conventional method for inserting DNA.

In one interesting embodiment, the inserted DNA sequence coding for a second kind of binding domain codes for a metal binding peptide sequence of an appropriate size
 20 such as a peptide sequence comprising a number of amino acids which is in the range of 2 to 100 such as in the range of 10 to 50 amino acids including 20 to 40 amino acids. It has been found that the insertion of one or more codons for histidine in particular may confer metal binding characteristics to the adhesin protein. Thus, as an example, the inserted peptide sequence may comprise at least 3 consecutive histidine
 25 residues such as at least 5 consecutive histidine residues. Such consecutive histidine residues are also referred to as polyHis peptides. In addition to histidine residues, amino acids which can confer metal binding characteristics to an adhesin protein include aspartate, cysteine, glutamate, methionine, serine, threonine, tyrosine and tryptophan. The coordination of metals can also be achieved by main chain carbonyl
 30 oxygens and amide nitrogens (Barbas III et al., 1993).

The cell according to the invention that expresses an adhesin capable of binding a metal compound can be constructed to bind any metal compound including transition elements belonging to the element groups Ib and II to VIII. Thus the metal compounds

which can be bound include as examples a Cr compound, a Pb compound, a Mn compound, a Ni compound, a Co compound, a Zn compound, a Hg compound and a precious metal compound.

- 5 It was found that cells selected for their capability to bind to specific metal compounds frequently expressed metal binding adhesins comprising particular binding motifs. Thus, such binding motifs were identified in the sequences enriched for binding to PbO₂, CoO, MnO₂ and ZnO. In some cases these sequences were associated with the Arg-Ser linker encoded sequence. Accordingly, in one preferred
- 10 embodiment, the cell expresses an adhesin where the second kind of binding domain comprises a motif selected from the group consisting of H/R-X₃-HRS (SEQ ID NOS:2-3) and S/T-K/R-X₂-HRS (SEQ ID NOS:4-7). Other peptide sequences which, when inserted in an adhesin protein confer metal compound binding capabilities are listed in Tables 2 and 3.
- 15 In accordance with the invention, the gene coding for the chimeric adhesin protein can be located on an extrachromosomal element including a bacteriophage, a plasmid and a cosmid. However, it may be preferred that the gene is integrated in the chromosome in order to maintain the gene stably in the cell.
- 20 A significant objective of the present invention is to provide cells expressing a chimeric adhesin protein that is capable of preferentially binding to target compounds to which the naturally occurring adhesin does not bind. By using a peptide library as it is described in the following, it is generally possible to isolate cells capable of binding
- 25 to a pre-selected target compound. This offers an advantageous means of constructing cells or adhesins that are highly useful for separating or removing certain compounds from an environment. Thus, the cells according to the invention can be used as bioremediation or biosorption means for separating undesired compounds such as organic pollutants including pesticides and herbicides or toxic compounds including
- 30 e.g. heavy metals from the outer environment, or as means for isolating precious compounds such as precious metals for recycling purposes.

Accordingly, the invention pertains in one aspect to a method of removing or isolating a compound including a metal compound from an environment, comprising adding to

said environment a cell according to the invention which expresses an adhesin that is capable of binding the particular compound to the second kind of binding domain, and separating the cell from the environment. It is also possible to isolate the surface structure comprising the adhesin protein and use the isolated structure or even the
5 adhesin protein in isolated form for such a purpose. In specific embodiments, the cells or the adhesin are capable of binding a metal compound as defined herein.

It will be appreciated that for the purpose of isolating compounds from a given environment, a mixture of cells each of which has the capability to bind a specific
10 compound can be used so as to simultaneously remove two or more compounds.

In useful embodiments of the above method, the cells or optionally, cell surface structure or adhesin proteins isolated from the cells, are immobilized to a substrate element comprising a receptor for the first kind of binding domain. The choice of such
15 substrate elements depends on the selected type of adhesin. In this context, suitable examples of substrate elements include microbial cells including bacterial cells, animal cells and plant cells and polymer particles.

Another important objective of the invention is to provide the means of having a
20 random peptide library displayed in cells carrying outer surface adhesin structures. Accordingly, in a further aspect of the invention there is provided a population of recombinant cells, the population comprising a multiplicity of clones of a cell according to the invention, each of which clones expresses an adhesin comprising a different second kind of binding domain. A highly advantageous feature of such a display
25 system according to the invention is the fact that the expressed adhesin proteins comprise at least one first kind of binding domain and at least one second kind of binding domain which permits that the cells or the isolated adhesin proteins can be immobilized by binding to a substrate element comprising target molecules for either of the binding domains leaving the other binding domain(s) free for isolating or
30 removing the target compounds for the free binding domain.

It is possible to provide, by inserting a library of DNA sequences encoding different peptide sequences into a cell population, a cell population that contains a large number of individual clones each of which expresses a specific chimeric adhesin protein

comprising an inserted second kind of binding domain. Methods for constructing random libraries of DNA sequences are known in the art, and a typical example of such a method is described in the following examples.

- 5 Thus, in another useful aspect there is provided a method of constructing a cell population as defined above, comprising the steps of constructing a random library of DNA sequences coding for a peptide, inserting the library into a gene coding for an adhesin protein, and transforming a host cell population with the library.
- 10 It has been found that the FimH adhesin as defined above is one useful adhesin protein for displaying a random peptide library on the surface of cells. One significant advantage of using the FimH protein for that purpose is that the fimbriae comprising the adhesin occurs in high numbers on the surface of cells capable of expressing type 1 fimbriae. As it is mentioned above, it is possible to use a FimH adhesin which is
- 15 modified to have, relative to a wild-type FimH molecule, other binding characteristics for the first kind of binding domain.

In one preferred embodiment, the above cell population comprises at least 10^6 different clones such as at least 10^7 clones e.g. at least 10^8 different clones.

- 20 In one embodiment, the above method includes a further step of enriching the cell population displaying the peptide library for cells specifically binding to a particular compound to which the adhesin protein from which the multifunctional adhesin protein is derived, substantially does not bind. Such a step typically comprises
- 25 contacting the cell population with said compound whereby cells expressing a second kind of binding domain that is capable of binding to the compound form aggregates with said compound, separating the cell-compound aggregates and isolating cells capable of binding to the compound. It will be understood that this enrichment step can be carried out using any type of target compound which it is desired to remove or
- 30 separate from a particular environment. In this context, one interesting example is to enrich the cell population against a metal compound such as it described in the following examples.

The enrichment step can be repeated two or more times if it is desired to obtain a cell population having a high capacity to bind the compound against which the population is enriched.

- 5 As a result of the above enrichment procedure it is possible to obtain a population of cells where at least 10% of cells express a chimeric adhesin protein capable of binding to the selected target compound. Preferably, the proportion of such cells is at least 25% including at least 40% e.g. at least 50%.
- 10 In one specific embodiment of the above method, the first kind of binding domain is blocked during the enrichment procedure.

As it has been mentioned above, the cells according to the invention can be used i.a. for several bioremediation or recycling purposes. However, it will be understood that it

- 15 is also possible for the same purposes to use fimbrial structures isolated from such cells. Accordingly, the invention relates in a further aspect to an isolated fimbrial structure comprising a multifunctional adhesin protein that contains at least one first kind of binding domain and at least one second kind of binding domain, said first kind of binding domain is capable of binding to an organic receptor and said second kind of
- 20 binding domain is capable of binding to a compound to which the naturally occurring adhesin protein substantially does not bind. In accordance with the invention such a fimbrial structure is one having at least one second kind of binding domain that binds to a metal or metal compound including a metal salt or a metal oxide.
- 25 A cell according to the invention or a fimbrial structure as defined above can be used for removing or separating a compound such as e.g. a metal or metal compound from an environment. In its broadest aspect such a use comprises the addition to the environment of such a cell or fimbrial structure, which is capable of binding the compound to the second kind of binding domain whereby aggregates of cells or
- 30 fimbrial structures with the compound are formed and separating the formed aggregates from the environment. In this context, the environment from which a compound can be separated by such use includes any aqueous environments such as e.g. lakes, ponds and water streams in the outer environment and water supply systems generally. An aqueous environment can also be a volume of liquid in a

container including food product and pharmaceutical products and chemical reaction mixtures. Thus it is envisaged that the cells or the fimbrial structures according to the invention are generally useful as means for separating a compound from a liquid medium.

5

It is also contemplated that other environments such as soil and other particulate mineral materials can be purified by contacting the materials, optionally in the form of slurries, with the cells or fimbriae according to the invention to obtain adsorption of a compound which it is desired to remove from the material such as a compound as
10 mentioned above, followed by separating the cells or the fimbriae from the material using conventional methods for separating cells or cell parts from an inorganic material.

In practical embodiments of such use the cell or the fimbrial structure are immobilized
15 to a supporting structure as also mentioned above, by binding to a receptor for the first kind of binding domain found on such a supporting structure. It is also possible, if the compound to be separated from the environment is one that binds to the first kind of binding domain, to immobilize the cell or fimbrial structure onto a structure comprising a target compound for the first kind of binding domain.

20

The invention will now be further illustrated in the following non-limiting example and the drawings where:

Fig. 1 is an overview of the plasmids used in this study; only relevant non-vector
25 sectors are shown. (A) The *fim* gene cluster as present on pPKL115 is shown. The triangle indicates the position of the translational stop linker in the *fimH* gene. (B) The *fimH* expression vector pLPA30 is shown together with the insert sequences of plasmids identified in this study which conferred adherence of recombinant cells to metals. Plasmids pMAS38-47 and plasmids pMAS48-51 were isolated after 4 and 5
30 enrichments, respectively;

Fig. 2 is a phase contrast micrograph demonstrating heterobinary binding properties of cells expressing engineered FimH adhesins. S1918 (pNSU36 + pPKL115) mixed with Ni^{2+} -NTA agarose beads and yeast cells in the absence (A) or presence (B) of 20mM

α -D-methyl mannopyranoside; S1918 (pMAS1 + pPKL115) (C) and S1918 (pNSU36 + pPKL115) (D) mixed with α -D-methyl mannopyranoside coated agarose beads and NiO;

- 5 Fig. 3 illustrates adhesion of cells expressing wild type (pMAS1) and hybrid (pMAS37) FimH proteins to casein and yeast mannan. Values are the means \pm standard errors of the means (n = 4) of the number of bacteria bound per well;

Fig. 4 shows a phase contrast micrograph demonstrating adherence of S1918 cells
10 containing plasmids expressing various chimeric *fimH* genes to metal oxides. Plasmids indicated are pLPA30 (wild-type *fimH*), pMAS25 (one polyHis insert), pNSU36 (two polyHis inserts), pMAS38 and pMAS42 (random clones). Cells are shown in M63 salts medium alone, or in the same medium containing either NiO, CuO or CdO;

- 15 Fig. 5 shows atomic adsorption spectroscopy determinations of the amount of (A) Ni^{2+} or (B) Cd^{2+} associated with cells containing the plasmids pLPA30 (wild type *fimH*), pMAS38 (random clone), pMAS25 (one polyHis insert) or pNSU36 (2 polyHis inserts). Data from a single experiment are presented, however the experiment was repeated several times and the results were essentially the same;

20

Fig 6A is an overview of the plasmids used in the FimH display system. Only relevant non-vector regions are shown. Plasmid pPKL115 contains the entire *fim* gene cluster with a translational stop linker inserted in the *fimH* gene (indicated by a triangle). The FimH expression vector pLPA30 is shown along with the *Bgl*II insertion site at position
25 225 and the two primers (P1 and P2) used to monitor the size and distribution of the random library;

Fig. 6B I illustrates the monitoring of the insert population by PCR analysis using primers P1 and P2 during enrichment for binding sequences to Cr_2O_3 . The size and
30 distribution of the insert population is shown prior to enrichment (lane 0) and during the course of the four enrichments (lanes 1-4). The number of insert sequences are indicated;

Fig 6B II shows a PCR analysis of the insert population from the starting population (line 0) and four cycles of transfer to M63 salts and regrowth (lines 1-4), indicating the stability of the insert population in the absence of selection for binding to a specified target;

5

Fig. 7 is a phase contrast micrograph demonstrating adherence of S1918 cells containing plasmids expressing various chimeric *fimH* genes to CoO (I), MnO₂ (II), PbO₂ (III), and Cr₂O₃ (IV). Plasmids used were pLPA30 (wild-type *fimH*), pKKJ73 (random library clone isolated from selections for adherence to CoO), pKKJ78 (random library clone isolated from selections for adherence to MnO₂), pKKJ68 and pKKJ69 (random library clones isolated from selections for adherence to PbO₂), and pKKJ62 (random library clones isolated from selections for adherence to Cr₂O₃). Cells are shown in M63 salts medium alone, or in the same medium containing either CoO, MnO₂, PbO₂, or Cr₂O₃; and

15

Fig. 8 is a phase contrast micrograph showing adherence of S1918 cells containing plasmid expressing chimeric *fimH* gene enriched from a random peptide library for binding to ZnO. (A) plasmid pLPA30 (wild-type *fimH*) and (B) plasmid pJKS9 (random library clone isolated by selection for adherence to ZnO. The ZnO is indicated by an arrow.

20

EXAMPLE 1

25 The expression of heterobinary adhesins based on the *Escherichia coli* FimH fimbrial protein and their ability to bind NiO, CuO and CdO

1.1. Abstract

30 The FimH adhesin of *Escherichia coli* type 1 fimbriae confers binding to D-mannosides by virtue of a receptor binding domain located in its N-terminal region. This protein was engineered into a heterobifunctional adhesin by introducing a secondary binding site in the C-terminal region. The insertion of histidine clusters into this site resulted in the coordination of various metal ions by recombinant cells expressing chimeric FimH

proteins. In addition, libraries of random peptide sequences inserted into the FimH display system and screened by a "panning" technique identified specific sequences conferring adherence to Ni^{2+} and Cu^{2+} . Recombinant cells expressing heterobifunctional FimH adhesins could adhere simultaneously to both metals and
 5 saccharides. Finally, combining the metal-binding modifications with alterations in the natural receptor binding region demonstrated the ability to independently modulate the binding of FimH to two ligands simultaneously.

1.2. Materials and methods

10

(i) Strains and plasmids

The *E. coli* strain S1918 ($F^- \text{lacI}^\Delta \Delta\text{-malB101 endA hsdR17 supE44 thi1 relA1 gyrA96 fimB-H::kan}$) (Brown, 1992) was used in this study. Strains were grown in Luria-
 15 Bertani (LB) medium supplemented with the appropriate antibiotics (Sambrook et al., 1989). The FimH expression vector, pLPA30, is a pUC18 derivative containing the *fimH* gene downstream of the *lac* promoter and with a *Bgl*II linker inserted at position 225 (Pallesen et al., 1995). Plasmid pPKL115 is a pACYC184 derivative containing the whole *fim* gene cluster with a stop linker inserted in the *fimH* gene (Pallesen et al.,
 20 1995).

Plasmid pMAS25 was made by inserting an 18 bp synthetic double-stranded DNA segment encoding six consecutive histidine residues and containing a *Bgl*II overhang at one end and a *Bam*HI overhang at the other into the *Bgl*II site of pLPA30. The double-
 25 stranded poly-histidine segment resulted from the annealing of two oligonucleotides (5'-GATCTCATCACCATCATCACCATG (SEQ ID NO:8) and 5'-GATCCATGGTGATGATGGTGATGA (SEQ ID NO:9)).

Plasmid pNSU36 was made by digestion of pMAS25 with *Bgl*II and insertion of a
 30 second poly-histidine DNA segment. Plasmid pMAS1 contained the *fimH* gene from *E. coli* strain PC31 (Klemm et al., 1985) inserted into pUC19.

Plasmid pMAS37 was made by overlapping PCR using a set of oligonucleotides which amplified the N-terminal half of *fimH* from *E. coli* strain CI#4 (19) and the C-terminal

half of *fimH* from pNSU36 and subsequent ligation into pUC19. PCR was performed as previously described (12) using the Expand High Fidelity PCR System (Boehringer, Mannheim). DNA sequencing was carried out by the dideoxy chain-termination technique (15) using a Sequenase version 2.0 kit (USB).

5

(ii) Construction of a random library

Construction of the random library was performed essentially as described by Brown (1992). Briefly, a template oligonucleotide containing the sequence

- 10 5'-GGACGCAGATCT(VNN)₉AGATCTAGCACCAGT-3' (SEQ ID NO:10) was chemically synthesized where N indicates an equimolar mixture of all four nucleotides and V indicates an equimolar mixture of A, C and G. A primer oligonucleotide 5'-ACTGGTGCTAGATCT-3' (SEQ ID NO:11) was hybridized to the template oligonucleotide and the primer extended with Klenow fragment of DNA polymerase I.
- 15 The double stranded oligonucleotide was extracted twice with phenol-chloroform and ethanol precipitated. Digestion with *Bgl*II released an internal 33 bp fragment which was purified by electrophoresis through a 12% polyacrylamide gel in TBE. The 33 bp fragment was excised and eluted from the gel with a buffer containing 10 mM Tris-HCl, pH 8.0, 2 mM EDTA, 0.15 M NaCl. The eluate was filtered through a 0.22 µm
- 20 Qiagen filter, concentrated by ethanol precipitation and redissolved in 10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 0.1 M NaCl. The redissolved 33 bp *Bgl*II fragment was ligated at various ratios to *Bgl*II digested pLPA30. The ligation products were precipitated with ethanol and electroporated into S1918 (containing pPKL115).

- 25 The diversity of the library was calculated to be 4×10^7 individual clones based on extrapolation from numbers of transformants obtained in small scale platings. The transformation mixture was made up to 10 ml and grown for approximately 7 generations (4×10^9 cells). 1 ml aliquots were frozen at -80°C in 25% glycerol. Each 1 ml aliquot contained approximately 4×10^8 cells, which represented 10-times the
- 30 library diversity. Random screening of clones by PCR indicated a predominance of one to three 33 bp oligonucleotide inserts; sequencing of the inserts from randomly selected clones revealed G + C contents ranging from 30-70%.

(iii) Enrichment procedure

The binding of bacterial cells to nickel ions was performed using a commercially available Ni^{2+} -NTA solid matrix (Qiagen). The NTA ligand has four chelating sites
 5 which interact with one nickel ion. This leaves two out of the six ligand binding sites in the coordination sphere of the Ni^{2+} ion to interact with the histidine tag.

The enrichment procedure for identifying Ni^{2+} -binding clones from the random library was as follows. Mid-exponential cultures were diluted in M63 salts (Miller, 1972)
 10 containing 20 mM α -methyl mannopyranoside and 50% Percoll (Pharmacia). The α -methyl mannopyranoside was added to block the natural binding of the FimH adhesin, while the use of percoll permitted the formation of a density gradient upon centrifugation. This resulted in the formation of a distinct band by the Ni^{2+} -NTA resin and allowed the specific separation of any adhering bacteria from non-adherent
 15 bacteria. Under these conditions, bacteria expressing wild-type FimH proteins as components of type 1 fimbriae did not co-separate with the Ni^{2+} -NTA resin. The resin and bacteria expressing the random library within FimH were mixed and allowed to adhere at room temperature with gentle agitation. Centrifugation was then performed, the resin and any adhering bacteria removed and plated onto L-agar containing
 20 appropriate antibiotics. After overnight incubation colonies were pooled from the surface of the plates, exponentially growing cultures established and the enrichment procedure repeated. Following each cycle of enrichment aliquots of the populations were stored at -80°C . Plasmid DNA was prepared from each aliquot and used in PCR to monitor the size distribution of the inserts in the population.

25

(iv) Binding assays

Mid-exponential phase cultures were washed, resuspended in M63 salts and then mixed simultaneously with Ni^{2+} -NTA agarose beads (Qiagen) and yeast cells
 30 (*Saccharomyces cerevisiae*) or α -D-methyl mannopyranoside agarose beads (Sigma) and NiO , respectively. Samples were incubated at room temperature for 15 minutes with gentle agitation prior to examination by phase contrast microscopy. When it was necessary to block the natural FimH binding site, α -D-methyl mannopyranoside was used in the procedure at a final concentration of 20 mM. The binding of cells to the

Ni²⁺-NTA resin was reversed using an imidazole gradient (1 mM - 50 mM) (Janknecht et al., 1991). Binding of cells to casein and yeast mannan was performed in microtitre plates as described by Sukurenko et al. (1995), with the exception that bound cells were eluted without prior incubation.

5

(v) Binding to metals

Metal oxides (NiO, CuO and CdO) were purchased from Aldrich. Particles of appropriate size for microscopy were prepared by differential centrifugation. Metal
 10 oxides were suspended in M63 salts prior to the addition of bacteria. Samples were incubated at room temperature for 15 minutes with gentle agitation and examined microscopically. As an alternative procedure for demonstrating metal-binding capacity, the bioaccumulation of either Ni²⁺ or Cd²⁺ by recombinant bacteria was measured by atomic absorption. Late exponential phase cultures were washed in M63 salts and
 15 resuspended in the same medium containing 20 µM NiCl₂ or CdCl₂, respectively. The cells were incubated for 30 min to allow adsorption of the metal ions and washed twice in M63 salts. Samples were prepared and analyzed on a Perkin Elmer 2100 atomic absorption spectrophotometer as previously described (Romeyer et al., 1988).

20 1.3. Results

(i) Construction of a FimH-polyHis hybrid protein

Two positions in the C-terminal domain of the FimH protein which can tolerate the
 25 insertion of heterologous sequences have been identified (Pallesen et al., 1995). In this study was used the FimH expression vector pLPA30 which contains the *fimH* gene with an in-frame *Bgl*II linker inserted at a position encoding amino acid residue 225 and placed under transcriptional control of the *lac* promoter. In order to express chimeric FimH as functional constituents of fimbriae, there was also used an auxiliary
 30 plasmid (pPKL115) encoding the rest of the *fim* gene cluster (Fig. 1).

A synthetic DNA segment encoding six tandem histidine residues was constructed by annealing two complementary 24 bp oligonucleotides designed to create a final double stranded DNA segment with a *Bgl*II overhang at one end and a *Bam*HI overhang at the

other end. This feature permitted the introduction of one or two such segments in plasmid pLPA30, resulting in plasmids pMAS25 and pNSU36, respectively. Sequence analysis confirmed the insert orientation and conservation of the reading frame in the chimeric *fimH* genes. Receptor blots of the two chimeric FimH proteins to α -D-

5 mannosylated bovine serum albumin indicated they were synthesized as full-length products. The presence of biologically active chimeric FimH proteins on the surface of recombinant cells was demonstrated by the ability to cause strong agglutination of yeast cells.

10 (ii) Heterobifunctionality of the FimH adhesin

To demonstrate simultaneous heterobifunctional binding of the engineered FimH protein we presented the recombinants with targets for both the natural receptor site and the C-terminal polyHis insert at the same time (Fig. 2). Binding was observed in

15 both directions, i.e. binding to the metal resin followed by the D-mannose target (yeast) or binding to D-mannose beads followed by NiO. Binding to the Ni^{2+} -NTA resin was shown to be dependent on the introduced poly-histidine clusters as a strain carrying the wild-type *fimH* gene did not adhere to the resin. In addition, binding to the Ni^{2+} -NTA resin could be reversed by the addition of imidazole. The adherence of yeast

20 cells to bacteria bound to the Ni^{2+} -NTA resin could also be blocked by the addition of methyl- α -D-mannopyranoside (Fig. 2). Taken together, these results demonstrate that two independent adhesive domains on the FimH protein can be used to bind cells to different target molecules simultaneously.

25 (iii) Modification of the natural receptor-binding site of FimH

The *fimH* gene used as a basis for manipulations was originally cloned from *E. coli* K-12 strain PC31. The corresponding FimH confers binding to α -D-mannosides but not to other targets such as proteins. However, certain wild-type versions of FimH confer

30 binding to protein targets and display higher affinity to α -D-mannosides due to minor changes in the N-terminal receptor recognition domain (Sokurenko et al., 1992, 1994 and 1995). In order to demonstrate the ability to manipulate the natural binding site of the FimH adhesin it was decided to exchange this domain with that of the naturally occurring wild-type variant CI#4 (Sokurenko et al., 1994). Overlapping PCR was used

to construct a hybrid *fimH* gene in which the first half originated from CI#4 and the second half from pNSU36, respectively. The FimH adhesin from CI#4 has previously been shown to bind to protein targets such as casein and possess enhanced affinity for mannan (Sokurenko et al., 1994). The new hybrid FimH protein was shown to
5 display the same binding phenotype to both casein and D-mannose (Fig. 3), while at the same time also retaining its ability to bind to Ni^{2+} ions.

These results demonstrate that the natural binding domain in the N-terminal part of the FimH adhesin can be manipulated with ensuing change in receptor affinity. At the
10 same time a heterologous insert in the C-terminal part of the same molecule confers binding to a secondary target, viz, nickel.

(iv) Selection of Ni^{2+} adhering bacteria from a random library

15 As it had been demonstrated that the FimH protein could be engineered to confer metal-binding properties on a recombinant cell it was assumed that the Ni^{2+} -NTA resin would be a suitable target to evaluate the use of the fimbrial system for the display of random peptide sequences. A random library was constructed by inserting various numbers of synthetic double stranded oligonucleotides into the *Bgl*II site in position
20 225 of the *fimH* gene. The double stranded oligonucleotides consisted of 9 random codons flanked by *Bgl*II restriction sites, encoding arginine and serine. This genetic structure permits the construction of libraries containing different sizes of double stranded 33 bp oligonucleotides, a feature which greatly enhances the complexity of the libraries. In addition, the distribution of the population through the enrichment
25 procedure can be monitored by PCR amplification across the insert region using primers complementary to the vector sequence flanking the insertion site.

Serial selection and enrichment of the random library was performed against the Ni^{2+} -NTA resin. PCR monitoring of the insert population revealed in a distinct change in the
30 size distribution after 4 cycles of selection and enrichment. In a control experiment, 10 cycles of growth of the population, washing in M63 salts in the absence of Ni^{2+} -NTA resin and regrowth did not alter the size distribution of the insert sequences. Of fifty randomly selected colonies from the fourth enrichment, 11 were shown to bind to the Ni^{2+} -NTA resin and examined further. The FimH-containing plasmids were

isolated from each strain and the insert region sequenced. Ten different insert sequences were identified (Fig. 1). Interestingly, the insert sequence encoded by plasmid pMAS38 was identified in 2 of the 11 plasmids. This sequence contained a unique *ScaI* restriction site which could be used to monitor the prevalence of the insert in the subsequent fifth enrichment. Eight out of 12 clones identified as binding to Ni^{2+} from the fifth enrichment contained this unique restriction site, indicating that this insert was the dominant sequence enriched throughout the selection procedure. The remaining 4 inserts were also examined and contained sequences which differed from those identified in the previous enrichment (Fig. 1). All of the insert sequences contained histidine residues, providing further evidence for the role of this amino acid in the binding of proteins to Ni^{2+} .

(v) Binding of selected clones to metal oxides

The 14 different plasmids identified from the random library which conferred affinity to Ni^{2+} were purified and re-transformed into S1918 (pPKL115). The new recombinant clones displayed the same binding phenotype as the original isolates, indicating that the binding phenotype was indeed plasmid encoded. Although these clones were originally selected in M63 salts containing 20 mM α -methyl mannopyranoside and 50% percoll, they also displayed the same binding phenotype in M63 salts alone, indicating that these reagents had no effect on the stability of metal-binding capacity. The binding of these clones to the Ni^{2+} -NTA resin could be inhibited by the addition of imidazole, as previously observed with the clones harbouring one and two histidine clusters. The agglutination titres of these cells were similar to a control strain expressing wild-type FimH, indicating that the presence of the inserts had not influenced the natural binding domain of FimH or significantly altered the number of fimbriae on the surface of the cells.

To investigate whether the isolated plasmids conferred recognition of other metals, transformants of S1918 (pPKL115) harbouring these plasmids were examined in binding assays to NiO, CuO and CdO by phase contrast microscopy. All of the clones formed aggregates when mixed with either NiO or CuO, but not CdO. The binding of clones harbouring plasmids pMAS38 and pMAS42 is shown in Fig. 4. Recombinant clones harbouring pMAS25 and pNSU36 (one and two histidine clusters, respectively)

were observed to form aggregates with all 3 metal oxides. The different sizes of the cell-metal aggregates indicated differences in the avidity of the various clones towards each of the metals. In a separate assay to monitor avidity towards metal ions, atomic adsorption spectroscopy was used to measure the amount of Ni^{2+} or Cd^{2+} associated with clones harbouring either pMAS25, pNSU36 or pMAS38. A significant difference in the amount of metal associated with these cells was observed when compared to a cell expressing wild-type FimH-containing fimbriae (Fig. 5).

Strain S1918 containing pPKL115 and pMAS38 and strain S1918 containing pPKL115 and pNSU36, respectively were deposited under the Budapest Treaty with the European Collection of Cell Cultures (ECACC) under the accession Nos. 98043014 and 98043015, respectively.

15 EXAMPLE 2

The expression of heterobinary adhesins based on the *Escherichia coli* FimH fimbrial protein and their ability to bind Cr_2O_3 , PbO_2 , CoO and MnO_2

20 2.1. Materials and methods

Bacterial strains, plasmids and growth conditions were as described in Example 1. The enrichment procedure was carried out essentially as described in Example 1, i.e. with the exception that the cells were inoculated with metal oxides and binding clones enriched by separation in 75% Percoll in M63 salts. The random peptide library as described in Example 1 was used throughout this experiment.

(i) Binding to metals

30 The metal oxides PbO_2 , MnO_2 , Cr_3O_2 and CoO were purchased from Aldrich. Particles of appropriate size for microscopy were prepared by differential centrifugation. Metal oxides were suspended in M63 salts prior to the addition of bacteria. Samples were incubated at room temperature for 15 minutes with gentle agitation and examined microscopically.

(ii) Agglutination of yeast cells.

The capacity of bacteria to express a D-mannose binding phenotype was assayed by their ability to agglutinate yeast cells (*Saccharomyces cerevisiae*) on glass slides. Aliquots of washed bacterial suspensions at $OD_{550} = 1.0$ and 10% yeast cells were mixed and the time until agglutination occurred measured.

2.2. Results

10

(i) Isolation and analysis of metal binding sequences

Serial selection and enrichment of the random library was performed against either PbO_2 , MnO_2 , Cr_3O_2 or CoO . To isolate cells adhering to each of the metal oxides a 50% Percoll solution which formed a density gradient upon centrifugation was used. Under these conditions only cells adhering to the metal oxides were able to sediment when centrifuged. Monitoring of the insert population by PCR revealed a distinct change in its size distribution after 4 cycles of selection and enrichment against each of the metal oxides. In a control experiment, the same number of cycles of growth of the population, washing in M63 salts in the absence of metal oxides and regrowth did not alter the size distribution of the insert sequences (Fig. 6).

Twenty colonies were randomly selected from the fourth enrichments against each of the metals and examined for metal-binding by phase contrast microscopy. Only colonies displaying a metal-binding phenotype were examined further. The *fimH*-containing plasmids were isolated from these strains and the insert region sequenced. Each of the metal-binding sequences are shown in the below Table 2.

Table 2. Sequences conferring the ability of cells to adhere to metal oxides (SEQ ID NOS. 12-32)

Metal oxide	Sequences	Plasmid
Cr_2O_3	RSVVRPKAATNRS	pKKJ62
	RSRIRHRLVGQRS	pKKJ66
	RSVKDGSATAKRSVANFETPRVRS	pKKJ61
	RSAPQTGRPNNRS LPLGNRDMQRS	pKKJ67
PbO_2	RSVQNDRIVAGRS	pKKJ63
	RSYPPFHNNDHRS	pKKJ64
	RSNTRMTARQHRSANHKSTQARAS	pKKJ68
	RS LAIDGTDVQRSKPLARSSGARS	pKKJ69
	RS P SPIRVPHHRS TAIPNRQLIRS QIRIHAMGHR	pKKJ65
	RSRRVRDIHLGRSVQHRLGQPLRSLHQOSSPTLRS	pKKJ70
	RSRTPLAPVPPVRSWHIGSRTIARSFNGITIGDNRSYIPEHWYWSRS	pKKJ71
CoO	RSGRMQRRVAHRS	pKKJ75
	RS LGKDRPHFHR	pKKJ72
	RSRGLRNILMLRSYDSRSMRPHRS	pKKJ73
	RSEPRRATQAPRSKPQKNEPAPRS	pKKJ74
	RS LGAVSSLFSRSQKIMQTDIVRSKGVPRPGAQR	pKKJ76
MnO_2	RSHHMLRRRNTRS	pKKJ80
	RSHINASQRVAR	pKKJ81
	RSCPRLGVWFYRSLSVGDGFVRRS	pKKJ79
	RSTSGPSRVMTRSIILRIGTLDRSCLKVFHMGWRS	pKKJ77
	RSITPILHDHRRSSVRPMVAHRRSPTLYFPAASRS	pKKJ78

A number of different peptide sequences were enriched which could confer the ability to bind to the various metal oxides tested. In the case of binding to PbO_2 , seven different sequences were identified. Of these sequences plasmids pKKJ63 and pKKJ69 were represented three and two times, respectively. The size of these inserts

5 ranged from one to four double stranded 33-mer oligonucleotides in length. Examination of the sequences revealed some structural similarities in the amino acids forming the coordinating ligands. Two motifs, comprising the amino acid sequences H/R- X_3 -HRS (SEQ ID NOS:2-3) or S/T-K/R- X_2 -AR (SEQ ID NOS:33-36) could be discerned from the data (Table 1). Interestingly, the R- X_3 -HRS (SEQ ID NO: 37)

10 binding motif was also observed in two of the five sequences independently enriched for binding to CoO .

A consensus sequence for binding to MnO_2 was also identified. Three of the five sequences contained a H/V-RRS motif. Of interest also was the presence of an

15 unpaired cysteine residue in two of the sequences. No cysteine residues were identified in any of the other metal binding sequences. The FimH protein contains four cysteine residues which participate in the formation of two disulphide bridges in its tertiary structure. Although cysteine has been shown to participate in metal binding, it is likely that this display system would be biased against the insertion of cysteine

20 residues into FimH. No binding motif could be elucidated from the Cr_2O_3 binding sequences.

(ii) Re-transformation into S1918(pPKL115) and phenotypic characterization

25 The plasmids identified from the random library which conferred the ability to bind to each of the above metal oxides were purified and re-transformed into S1918(pPKL115). The new recombinant clones displayed the same binding phenotype as the original isolates, indicating that the binding phenotype was indeed plasmid encoded. Figure 7 shows the binding of one representative clone from each of the

30 selections. Despite originally being selected in M63 salts containing 20 mM methyl- α -D-mannopyranoside and 50% Percoll, these clones also displayed the same binding phenotype in M63 salts alone, indicating that these reagents had no effect on the stability of metal-binding capacity. The different sizes of the cell-metal aggregates

indicated that there were differences in the avidity of the various clones towards each of the metals.

The agglutination titres of these cells were similar to a control strain expressing wild-type FimH, indicating that the presence of the inserts had not influenced the natural binding domain of FimH or significantly altered the number of fimbriae on the surface of the cells.

10 EXAMPLE 3

The expression of heterobinary adhesins based on the *Escherichia coli* FimH fimbrial protein and their ability to sequester zinc

15 By engineering FimH to display a random peptide library, zinc-chelating bacteria were isolated. The library comprising 4×10^7 different sequences was screened for binding to ZnO. Sequences being capable of ZnO binding were characterised.

The random library was constructed essentially as described in Example 1 by synthesising double stranded 33 bp oligonucleotides consisting of nine random codons flanked by *Bgl*II restriction sites. The library was inserted in a *Bgl*II site engineered into a position encoding amino acid 225 in *fimH*. The diversity of the random library was calculated by small scale plating of transformants to constitute about 4×10^7 individual clones. The technique allows for insertion of different numbers of double stranded oligonucleotides resulting in a more complex library. A pUC18 based vector, pLPA, comprising the *fimH* gene under transcriptional control of a *lac* promoter was used for the construction and expression of the library. The remainder of the *fim* genes were provided *in trans* by the compatible auxiliary plasmid, pPKL115. *E. coli* S1918 was used as the host strain.

30

Mid-exponentially growing cells containing the random peptide library were harvested and diluted in M63 salts to about 10^6 cells/ml. The cells were inoculated at room temperature and gently agitation with 70% (v/v) Percoll (Pharmacia) and 20 mM methyl- α -D-mannopyranoside. The latter compound was added to prevent non-specific

binding. After blocking, ZnO (Sigma) was added at a final concentration of 3 nM metal oxide and the cells were allowed to adhere for 15 min. The use of Percoll permitted the formation of a density gradient upon centrifugation, which resulted in pelleting of the ZnO and allowed separation of adhering bacteria from non-adhering bacteria.

- 5 Under these conditions, bacteria expressing wild-type FimH proteins as components of type 1 fimbriae did not pellet with the metal oxide. The pellet containing metal and adhering cells was resuspended in fresh LB broth containing appropriate antibiotics and incubated overnight at 37°C. This procedure was repeated and aliquots from each enrichment were stored at -80°C. Distribution of the number of inserts in the
- 10 population was monitored throughout the enrichment procedure by PCR amplification across the insert region using primers complementary to the vector sequence flanking the insertion site. A control experiment, where neither Percoll nor metal oxide was applied, showed no change in the size distribution during the enrichment, indicating that the procedure in itself did not have any selection abilities. Compared to the
- 15 control, the PCR showed enrichment for one and two inserts after 5 cycles of selection and enrichment against ZnO. Cells from the fifth enrichment step were plated out and 40 single colonies were randomly selected and grown overnight in LB broth containing appropriate antibiotics. The ability of the cells expressing the enriched peptide to adhere to ZnO was examined by phase contrast microscopy and compared
- 20 to a control strain expressing wild-type FimH.

About 50% of the selected clones displayed a ZnO binding phenotype and the *fimH*-containing plasmid was isolated from these clones. In order to test if the ZnO binding phenotype actually was encoded by the plasmids these were re-transformed into

- 25 S1918(pPKL115) cells. Examination in phase contrast microscope showed that the re-transformed clones displayed the same binding pattern as the original isolates (Fig. 8). This indicated that the ZnO binding phenotype indeed was plasmid encoded. The insert regions in *fimH* of 23 individual clones were sequenced and nine different sequences were identified (Table 3).

Table 3. Sequences conferring the ability of cells to adhere to ZnO

Plasmid	Frequency	Enriched sequences ^a	
pJKS9	8/23	R S N T R M T A <u>R Q H R S</u> A N H K S T Q R A R S	SEQ ID NO:38
pJKS10	2/23	R S V F L P S I L G W R S R L D D Q G V A A R S	SEQ ID NO:39
pJKS12	3/23	R S T R N K H T T A R R S V A P G I G E <u>P S R S</u>	SEQ ID NO:40
pJKS25	1/23	R S I M H V R L <u>R A R R S</u> A R H M K D A D P R S	SEQ ID NO:41
pJKS28	1/23	R S P I I I R S <u>R I N R S</u> H G R T K A T <u>P A R S</u>	SEQ ID NO:42
pJKS29	2/23	R S R G L R N I L M L R S Y D S R S M <u>R P H R S</u>	SEQ ID NO:43
pJKS11	4/23	R S T R R G T H N K D R S	SEQ ID NO:44
pJKS27	1/23	R S T V P K K R H P K D R S	SEQ ID NO:45
pJKS26	1/23	R S Y D S R S M <u>R P H R S</u>	SEQ ID NO:46

^a Three different binding motifs from the enriched sequences are underlined (RX₂RS),
5 underlined and italic (PXRS) and italic (TX₄HXKDRS). Bold RS letters represent amino acids encoded by the *Bgl*II linkers.

Of the above identified nine sequences, the insert sequences of pJKS9, pJKS11, pJKS12 and pJKS10 were represented eight, four, three and two times, respectively.
10 The majority of the clones had two inserts. A number of motifs were discerned from examination of the insert sequences. RX₂RS, PXRS and TX₄HXKD motifs occurred five, four and two times, respectively. Furthermore, taking into account the design of the library, the number of histidine residues was 40% higher than the expected, which indicates enrichment of this amino acid.

REFERENCES

- Barbas III CF, JS Rosenblum and RA Lerner. 1993. Direct selection of antibodies that coordinate metals from semisynthetic combinatorial libraries. *Proc. Natl. Acad. Sci. USA*. **90**:6385-6389.
- Boder ET and KD Wittrup. 1997. Yeast surface display for screening combinatorial polypeptide libraries. *Nature Biotechnol.* **15**:553-557.
- 10 Brown S. 1992. Engineered iron oxide-adhesion mutants of the *Escherichia coli* phage I receptor. *Proc. Natl. Acad. Sci. USA* **89**:8651-8655.
- Georgiou G, C Stathopoulos, PS Daugherty, AR Nayak, BL Iverson and R Curtiss III. 1997. Display of heterologous proteins on the surface of microorganisms: From the screening of combinatorial libraries to live recombinant vaccines. *Nature Biotechnol.* **15**:29-34.
- 15 Janknecht R, G de Martynoff, J Lou, RA Hipskind, A Nordheim and HG Stunnenberg. 1991. Rapid and efficient purification of native histidine tagged proteins expressed by recombinant vaccinia virus. *Proc. Natl. Acad. Sci. USA*. **88**:8972-8976.
- 20 Jones CH, JS Pinkner, R Roth, J Heuser, AV Nicholes, S Abraham and SJ Hultgren. 1995. FimH adhesin of type 1 pili is assembled into a fibrillar tip structure in the *Enterobacteriaceae*. *Proc. Natl. Acad. Sci. USA* **92**:2081-2085.
- 25 Klemm P and G Christensen. 1987. Three *fim* genes required for the regulation of length and mediation of adhesion of *Escherichia coli* type 1 fimbriae. *Mol. Gen. Genet.* **208**:439-445.
- 30 Klemm P, BJ Jørgensen, I van Die, H de Ree and H Bergmans. 1985. The *fim* genes responsible for synthesis of type 1 fimbriae in *Escherichia coli*. *Mol. Gen. Genet.* **199**:410-414.

Knudsen TB and P Klemm. 1998. Probing the receptor recognition site of the FimH adhesin by fimbriae-displayed FimH-FocH hybrids. *Microbiology* **(144)**: 1919-1929.

Krogfelt KA and P Klemm. 1988. Investigation of minor components of *Escherichia coli* Type 1 fimbriae: protein chemical and immunological aspects. *Microb. Pathog.* **4**:231-238.

Krogfelt KA, H Bergmans and P Klemm. 1990. Direct evidence that the FimH protein is the mannose specific adhesin of *Escherichia coli* type 1 fimbriae. *Infect. Immun.* **58**:1995-1998.

Miller JH. 1972. Experiments in Molecular Genetics. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

15 Pallesen L., LK Poulsen, G Christiansen and P Klemm. 1995. Chimeric FimH adhesin of type 1 fimbriae: a bacterial display system for heterologous sequences. *Microbiology* **141**:2839-2848.

Romeyer FM, FA Jacobs, L Masson, Z Hanna and R Brousseau. 1988.

20 Bioaccumulation of heavy metals in *Escherichia coli* expressing an inducible synthetic human metallothionein gene. *J. Biotechnol.* **8**:207-220.

Sambrook J., EF Fritsch and T Maniatis. 1989. Molecular Cloning: A Laboratory Manual, 2nd Edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

25

Sanger F, S Nicklen and AR Coulson. 1977. DNA sequencing with chain-terminating inhibitors. *Proc. Natl. Acad. Sci. USA* **74**:5463-5467.

Schembri MA, L Pallesen, H Connell, DL Hasty and P Klemm. 1996. Linker insertion
30 analysis of the FimH adhesin of type 1 fimbriae in an *Escherichia coli* *fimH*-null background. *FEMS Microbiol. Lett.* **137**:257-263.

Sokurenko EV, HS Courtney, SN Abraham, P Klemm and DL Hasty. 1992. Functional heterogeneity of type 1 fimbriae of *Escherichia coli*. *Infect. Immun.* **60**:4709-4719.

Sokurenko EV, HS Courtney, J Maslow, A Siitonen and DL Hasty. 1995. Quantitative differences in adhesiveness of type 1 fimbriated *Escherichia coli* due to structural differences in *fimH* genes. J. Bacteriol. **177**:3680-3686.

5

Sokurenko EV, HS Courtney, DE Ohman, P Klemm and DL Hasty. 1994. FimH family of type 1 fimbrial adhesins: functional heterogeneity due to minor sequence variations among *fimH* genes. J. Bacteriol. **176**:748-755.

- 10 Sousa C, A Cebolla and V de Lorenzo. 1996. Enhanced metalload sorption of bacterial cells displaying poly-His peptides. Nature Biotechnol. **14**:1017-1020.

Thankavel K, B Madison, T Ikeda, R Malavia, AH Shah, PM Arumugam and SN Abraham. 1997. Localization of a domain in the FimH adhesin of *Escherichia coli* type

- 15 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection. J. Clin. Invest. **100**:1123-1136.

SEQUENCE LISTING

<110> Schembri, Mark Andrew
 Klemm, Per
 5
 <120> Novel multifunctional adhesin proteins
 and their display in microbial cells
 <130> 21352 PC 1
 10
 <150> PA 1998 00598
 <151> 1998-04-30
 <160> 46
 15
 <170> FastSEQ for Windows Version 3.0
 <210> 1
 <211> 300
 20
 <212> PRT
 <213> E. coli PC31 FimH
 <400> 1
 25 Met Lys Arg Val Ile Thr Leu Phe Ala Val Leu Leu Met Gly Trp Ser
 1 5 10 15
 Val Asn Ala Trp Ser Phe Ala Cys Lys Thr Ala Asn Gly Thr Ala Ile
 20 25 30
 Pro Ile Gly Gly Gly Ser Ala Asn Val Tyr Val Asn Leu Ala Pro Val
 35 40 45
 30 Val Asn Val Gly Gln Asn Leu Val Val Asp Leu Ser Thr Gln Ile Phe
 50 55 60
 Cys His Asn Asp Tyr Pro Glu Thr Ile Thr Asp Tyr Val Thr Leu Gln
 65 70 75 80
 Arg Gly Ser Ala Tyr Gly Gly Val Leu Ser Asn Phe Ser Gly Thr Val
 85 90 95
 35 Lys Tyr Ser Gly Ser Ser Tyr Pro Phe Pro Thr Thr Ser Glu Thr Pro
 100 105 110
 Arg Val Val Tyr Asn Ser Arg Thr Asp Lys Pro Trp Pro Val Ala Leu
 115 120 125
 40 Tyr Leu Thr Pro Val Ser Ser Ala Gly Gly Val Ala Ile Lys Ala Gly
 130 135 140
 Ser Leu Ile Ala Val Leu Ile Leu Arg Gln Thr Asn Asn Tyr Asn Ser
 145 150 155 160
 Asp Asp Phe Gln Phe Val Trp Asn Ile Tyr Ala Asn Asn Asp Val Val
 165 170 175
 45 Val Pro Thr Gly Gly Cys Asp Val Ser Ala Arg Asp Val Thr Val Thr
 180 185 190
 Leu Pro Asp Tyr Pro Gly Ser Val Pro Ile Pro Leu Thr Val Tyr Cys
 195 200 205
 50 Ala Lys Ser Gln Asn Leu Gly Tyr Tyr Leu Ser Gly Thr His Ala Asp
 210 215 220
 Ala Gly Asn Ser Ile Phe Thr Asn Thr Ala Ser Phe Ser Pro Ala Gln
 225 230 235 240
 Gly Val Gly Val Gln Leu Thr Arg Asn Gly Thr Ile Ile Pro Ala Asn
 245 250 255
 55 Asn Thr Val Ser Leu Gly Ala Val Gly Thr Ser Ala Val Ser Leu Gly
 260 265 270
 Leu Thr Ala Asn Tyr Ala Arg Thr Gly Gly Gln Val Thr Ala Gly Asn
 275 280 285

Val Gln Ser Ile Ile Gly Val Thr Phe Val Tyr Gln
 290 295 300

- 5 <210> 2
 <211> 7
 <212> PRT
 <213> Artificial Sequence
- 10 <220>
 <223> Binding motif
- <400> 2
 His Xaa Xaa Xaa His Arg Ser
 1 5
- 15 <210> 3
 <211> 7
 <212> PRT
 <213> Artificial Sequence
- 20 <220>
 <223> Binding motif
- <400> 3
 25 Arg Xaa Xaa Xaa His Arg Ser
 1 5
- <210> 4
 <211> 7
 30 <212> PRT
 <213> Artificial Sequence
- <220>
 <223> Binding motif
- 35 <400> 4
 Ser Lys Xaa Xaa His Arg Ser
 1 5
- 40 <210> 5
 <211> 7
 <212> PRT
 <213> Artificial Sequence
- 45 <220>
 <223> Binding motif
- <400> 5
 Ser Arg Xaa Xaa His Arg Ser
 50 1 5
- <210> 6
 <211> 7
 <212> PRT
 55 <213> Artificial Sequence
- <220>
 <223> Binding motif

5 <400> 6
 Thr Lys Xaa Xaa His Arg Ser
 1 5

<210> 7
 <211> 7
 <212> PRT
 <213> Artificial Sequence

10 <220>
 <223> Binding motif

15 <400> 7
 Thr Arg Xaa Xaa His Arg Ser
 1 5

20 <210> 8
 <211> 24
 <212> DNA
 <213> Artificial Sequence

25 <220>
 <223> Oligonucleotide for the construction of a
 double-stranded poly histidine segment (Example 1)

<400> 8
 gatctcatca ccatcatcac catg 24

30 <210> 9
 <211> 24
 <212> DNA
 <213> Artificial Sequence

35 <220>
 <223> Oligonucleotide for the construction of a
 double-stranded poly histidine segment (Example 1)

40 <400> 9
 gatccatggt gatgatggtg atga 24

<210> 10
 <211> 54
 <212> DNA

45 <213> Artificial Sequence

<220>
 <223> Template oligonucleotide

50 <400> 10
 ggacgcagat ctvnnvnnvn nvnnvnnvn vnnvnnvna gatctagcac cagt 54

55 <210> 11
 <211> 15
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer oligonucleotide

5 <400> 11
 actggtgcta gatct 15
 <210> 12
 <211> 13
 <212> PRT
 <213> Artificial Sequence
 10 <220>
 <223> Sequence conferring the ability of cells to adhere
 to metal oxides
 15 <400> 12
 Arg Ser Val Val Arg Pro Lys Ala Ala Thr Asn Arg Ser
 1 5 10
 <210> 13
 20 <211> 13
 <212> PRT
 <213> Artificial Sequence
 <220>
 25 <223> Sequence conferring the ability of cells to adhere
 to metal oxides
 <400> 13
 Arg Ser Arg Ile Arg His Arg Leu Val Gly Gln Arg Ser
 30 1 5 10
 <210> 14
 <211> 24
 <212> PRT
 35 <213> Artificial Sequence
 <220>
 <223> Sequence conferring the ability of cells to adhere
 to metal oxides
 40 <400> 14
 Arg Ser Val Lys Asp Gly Ser Ala Thr Ala Lys Arg Ser Val Ala Asn
 1 5 10 15
 Phe Glu Thr Pro Arg Val Arg Ser
 45 20
 <210> 15
 <211> 24
 <212> PRT
 50 <213> Artificial Sequence
 <220>
 <223> Sequence conferring the ability of cells to adhere
 to metal oxides
 55 <400> 15
 Arg Ser Ala Pro Gln Thr Gly Arg Pro Asn Asn Arg Ser Leu Pro Leu
 1 5 10 15
 Gly Asn Arg Asp Met Gln Arg Ser

20

- 5 <210> 16
 <211> 13
 <212> PRT
 <213> Artificial Sequence
- 10 <220>
 <223> Sequence conferring the ability of cells to adhere
 to metal oxides
- <400> 16
 15 Arg Ser Val Gln Asn Asp Arg Ile Val Ala Gly Arg Ser
 1 5 10
- <210> 17
 <211> 13
 20 <212> PRT
 <213> Artificial Sequence
- <220>
 <223> Sequence conferring the ability of cells to adhere
 25 to metal oxides
- <400> 17
 Arg Ser Tyr Pro Pro Phe His Asn Asn Asp His Arg Ser
 1 5 10
- 30 <210> 18
 <211> 24
 <212> PRT
 <213> Artificial Sequence
- 35 <220>
 <223> Sequence conferring the ability of cells to adhere
 to metal oxides
- 40 <400> 18
 Arg Ser Asn Thr Arg Met Thr Ala Arg Gln His Arg Ser Ala Asn His
 1 5 10 15
 Lys Ser Thr Gln Arg Ala Arg Ser
 20
- 45 <210> 19
 <211> 24
 <212> PRT
 <213> Artificial Sequence
- 50 <220>
 <223> Sequence conferring the ability of cells to adhere
 to metal oxides
- 55 <400> 19
 Arg Ser Leu Ala Ile Asp Gly Thr Asp Val Gln Arg Ser Lys Pro Leu
 1 5 10 15
 Ala Arg Ser Ser Gly Ala Arg Ser
 20

<210> 20
 <211> 35
 <212> PRT
 5 <213> Artificial Sequence

 <220>
 <223> Sequence conferring the ability of cells to adhere
 to metal oxides
 10
 <400> 20
 Arg Ser Pro Ser Pro Ile Arg Val Pro His His Arg Ser Thr Ala Ile
 1 5 10 15
 Pro Asn Arg Gln Leu Ile Arg Ser Gln Ile Arg Ile His Ala Met Gly
 15 20 25 30
 His Arg Ser
 35

 <210> 21
 20 <211> 35
 <212> PRT
 <213> Artificial Sequence

 <220>
 25 <223> Sequence conferring the ability of cells to adhere
 to metal oxides

 <400> 21
 Arg Ser Arg Arg Val Arg Asp Ile His Leu Gly Arg Ser Val Gln His
 30 1 5 10 15
 Arg Leu Gly Gln Pro Leu Arg Ser Leu His Gln Gln Ser Ser Pro Thr
 20 25 30
 Leu Arg Ser
 35
 35
 <210> 22
 <211> 46
 <212> PRT
 <213> Artificial Sequence
 40
 <220>
 <223> Sequence conferring the ability of cells to adhere
 to metal oxides

 45 <400> 22
 Arg Ser Arg Thr Pro Leu Ala Pro Val Pro Val Arg Ser Trp His Ile
 1 5 10 15
 Gly Ser Arg Thr Ile Ala Arg Ser Phe Asn Gly Ile Thr Ile Gly Asp
 20 25 30
 50 Asn Arg Ser Tyr Ile Pro Glu His Trp Tyr Trp Ser Arg Ser
 35 40 45

 <210> 23
 <211> 13
 55 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Sequence conferring the ability of cells to adhere

to metal oxides

- <400> 23
 Arg Ser Gly Arg Met Gln Arg Arg Val Ala His Arg Ser
 5 1 5 10
- <210> 24
 <211> 13
 <212> PRT
 10 <213> Artificial Sequence
- <220>
 <223> Sequence conferring the ability of cells to adhere
 to metal oxides
- 15 <400> 24
 Arg Ser Leu Gly Lys Asp Arg Pro His Phe His Arg Ser
 1 5 10
- 20 <210> 25
 <211> 24
 <212> PRT
 <213> Artificial Sequence
- 25 <220>
 <223> Sequence conferring the ability of cells to adhere
 to metal oxides
- <400> 25
 30 Arg Ser Arg Gly Leu Arg Asn Ile Leu Met Leu Arg Ser Tyr Asp Ser
 1 5 10 15
 Arg Ser Met Arg Pro His Arg Ser
 20
- 35 <210> 26
 <211> 24
 <212> PRT
 <213> Artificial Sequence
- 40 <220>
 <223> Sequence conferring the ability of cells to adhere
 to metal oxides
- <400> 26
 45 Arg Ser Glu Pro Arg Arg Ala Thr Gln Ala Pro Arg Ser Lys Pro Gln
 1 5 10 15
 Lys Asn Glu Pro Ala Pro Arg Ser
 20
- 50 <210> 27
 <211> 35
 <212> PRT
 <213> Artificial Sequence
- 55 <220>
 <223> Sequence conferring the ability of cells to adhere
 to metal oxides

- <400> 27
 Arg Ser Leu Gly Ala Val Ser Ser Leu Phe Ser Arg Ser Gln Lys Ile
 1 5 10 15
 Met Gln Thr Asp Ile Val Arg Ser Lys Gly Val Arg Pro Gly Ala Gln
 5 20 25 30
 Arg Arg Ser
 35
- <210> 28
 <211> 13
 <212> PRT
 <213> Artificial Sequence
- <220>
 15 <223> Sequence conferring the ability of cells to adhere
 to metal oxides
- <400> 28
 Arg Ser His His Met Leu Arg Arg Arg Asn Thr Arg Ser
 20 1 5 10
- <210> 29
 <211> 13
 <212> PRT
 25 <213> Artificial Sequence
- <220>
 <223> Sequence conferring the ability of cells to adhere
 to metal oxides
- 30 <400> 29
 Arg Ser His Ile Asn Ala Ser Gln Arg Val Ala Arg Ser
 1 5 10
- 35 <210> 30
 <211> 24
 <212> PRT
 <213> Artificial Sequence
- 40 <220>
 <223> Sequence conferring the ability of cells to adhere
 to metal oxides
- <400> 30
 45 Arg Ser Cys Pro Arg Leu Gly Val Trp Phe Tyr Arg Ser Leu Ser Val
 1 5 10 15
 Gly Asp Gly Phe Val Arg Arg Ser
 20
- 50 <210> 31
 <211> 35
 <212> PRT
 <213> Artificial Sequence
- 55 <220>
 <223> Sequence conferring the ability of cells to adhere
 to metal oxides

- <400> 31
 Arg Ser Thr Ser Gly Pro Ser Arg Val Met Thr Arg Ser Ile Ile Leu
 1 5 10 15
 Arg Ile Gly Thr Leu Asp Arg Ser Cys Leu Lys Val Phe His Met Gly
 20 25 30
 Trp Arg Ser
 35
- 10 <210> 32
 <211> 35
 <212> PRT
 <213> Artificial Sequence
- 15 <220>
 <223> Sequence conferring the ability of cells to adhere
 to metal oxides
- <400> 32
 20 Arg Ser Ile Thr Pro Ile Leu His Asp His Arg Arg Ser Ser Val Arg
 1 5 10 15
 Pro Met Val Ala His Arg Arg Ser Pro Thr Leu Tyr Phe Pro Ala Ala
 20 25 30
 Ser Arg Ser
 35
- 25 <210> 33
 <211> 6
 <212> PRT
 <213> Artificial Sequence
- 30 <220>
 <223> Binding motif
- 35 <400> 33
 Ser Lys Xaa Xaa Ala Arg
 1 5
- 40 <210> 34
 <211> 6
 <212> PRT
 <213> Artificial Sequence
- 45 <220>
 <223> Binding motif
- <400> 34
 Ser Arg Xaa Xaa Ala Arg
 1 5
- 50 <210> 35
 <211> 6
 <212> PRT
 <213> Artificial Sequence
- 55 <220>
 <223> Binding motif

<400> 35
 Thr Lys Xaa Xaa Ala Arg
 1 5

5 <210> 36
 <211> 6
 <212> PRT
 <213> Artificial Sequence

10 <220>
 <223> Binding motif

<400> 36
 Thr Arg Xaa Xaa Ala Arg
 15 1 5

<210> 37
 <211> 7
 <212> PRT
 20 <213> Artificial Sequence

<220>
 <223> Binding motif

25 <400> 37
 Arg Xaa Xaa Xaa His Arg Ser
 1 5

<210> 38
 30 <211> 24
 <212> PRT
 <213> Artificial Sequence

<220>
 35 <223> Sequence conferring the ability of cells to adhere
 to ZnO

<400> 38
 Arg Ser Asn Thr Arg Met Thr Ala Arg Gln His Arg Ser Ala Asn His
 40 1 5 10 15
 Lys Ser Thr Gln Arg Ala Arg Ser
 20

<210> 39
 45 <211> 24
 <212> PRT
 <213> Artificial Sequence

<220>
 50 <223> Sequence conferring the ability of cells to adhere
 to ZnO

<400> 39
 Arg Ser Val Phe Leu Pro Ser Ile Leu Gly Trp Arg Ser Arg Leu Asp
 55 1 5 10 15
 Asp Gln Gly Val Ala Ala Arg Ser
 20

<210> 40
 <211> 24
 <212> PRT
 <213> Artificial Sequence
 5
 <220>
 <223> Sequence conferring the ability of cells to adhere
 to ZnO
 10
 <400> 40
 Arg Ser Thr Arg Asn Lys His Thr Thr Ala Arg Arg Ser Val Ala Pro
 1 5 10 15
 Gly Ile Gly Glu Pro Ser Arg Ser
 20
 15
 <210> 41
 <211> 24
 <212> PRT
 <213> Artificial Sequence
 20
 <220>
 <223> Sequence conferring the ability of cells to adhere
 to ZnO
 25
 <400> 41
 Arg Ser Ile Met His Val Arg Leu Arg Ala Arg Arg Ser Ala Arg His
 1 5 10 15
 Met Lys Asp Ala Asp Pro Arg Ser
 20
 30
 <210> 42
 <211> 24
 <212> PRT
 <213> Artificial Sequence
 35
 <220>
 <223> Sequence conferring the ability of cells to adhere
 to ZnO
 40
 <400> 42
 Arg Ser Pro Ile Ile Ile Arg Ser Arg Ile Asn Arg Ser His Gly Arg
 1 5 10 15
 Thr Lys Ala Thr Pro Ala Arg Ser
 20
 45
 <210> 43
 <211> 24
 <212> PRT
 <213> Artificial Sequence
 50
 <220>
 <223> Sequence conferring the ability of cells to adhere
 to ZnO
 55
 <400> 43
 Arg Ser Arg Gly Leu Arg Asn Ile Leu Met Leu Arg Ser Tyr Asp Ser
 1 5 10 15
 Arg Ser Met Arg Pro His Arg Ser

20

5 <210> 44
 <211> 13
 <212> PRT
 <213> Artificial Sequence

 10 <220>
 <223> Sequence conferring the ability of cells to adhere
 to ZnO

 <400> 44
 Arg Ser Thr Arg Arg Gly Thr His Asn Lys Asp Arg Ser
 1 5 10
 15 <210> 45
 <211> 14
 <212> PRT
 <213> Artificial Sequence
 20 <220>
 <223> Sequence conferring the ability of cells to adhere
 to ZnO

 25 <400> 45
 Arg Ser Thr Val Pro Lys Lys Arg His Pro Lys Asp Arg Ser
 1 5 10
 30 <210> 46
 <211> 13
 <212> PRT
 <213> Artificial Sequence

 35 <220>
 <223> Sequence conferring the ability of cells to adhere
 to ZnO

 <400> 46
 Arg Ser Tyr Asp Ser Arg Ser Met Arg Pro His Arg Ser
 1 5 10
 40

CLAIMS

1. A recombinant cell expressing on its surface a multifunctional adhesin protein derived from a naturally occurring adhesin protein, the multifunctional adhesin protein
5 containing at least one first kind of binding domain and at least one second kind of binding domain, said first kind of binding domain is capable of binding to an organic receptor and said second kind of binding domain is one that is not naturally present in the adhesin protein from which the multifunctional adhesin protein is derived and is capable of binding to a compound to which the naturally occurring adhesin protein
10 substantially does not bind.
2. A cell according to claim 2 where the adhesin protein is part of a cell surface fibril selected from the group consisting of fimbriae or pili.
- 15 3. A cell according to claim 2 where the adhesin protein is derived from FimH.
4. A cell according to claim 3 where the first kind of binding domain is a naturally occurring binding domain.
- 20 5. A cell according to claim 3 where the first kind of binding domain has an amino acid sequence which differs from the *E. coli* PC31 FimH adhesin as defined herein in at least one amino acid whereby its saccharide binding characteristics is changed relative to those of the *E. coli* PC31 FimH adhesin.
- 25 6. A cell according to claim 3 where the second kind of binding domain is provided in the adhesin protein by inserting into the gene coding for said adhesin a DNA sequence coding for a peptide sequence conferring the capability of binding to a compound to which the naturally occurring adhesin protein substantially does not bind, whereby the adhesin is expressed as a chimeric protein comprising said first and
30 second kind of binding domains.
7. A cell according to claim 6 wherein the inserted DNA sequence codes for a metal binding peptide sequence

8. A cell according to claim 6 where the inserted DNA sequence codes for a peptide sequence comprising a number of amino acids which is in the range of 2 to 100.
9. A cell according to claim 8 wherein the peptide sequence comprises at least one histidine residue.
10. A cell according to claim 7 where the second kind of binding domain confers to the cell the capability of binding a metal compound selected from the group consisting of a Cr compound, a Pb compound, a Mn compound, a Ni compound, a Co compound, a Zn compound, a Hg compound and a precious metal compound.
11. A cell according to claim 10 where second kind of binding domain comprises a motif selected from the group consisting of H/R-X₃-HRS and S/T-K/R-X₂-HRS.
12. A cell according to any of claims 1-11 which is selected from the group consisting of a prokaryote cell and an eukaryote cell.
13. A cell according to claim 12 which is a bacterial cell selected from the group consisting of a gram-positive bacterium and a gram-negative bacterium.
14. A cell according to claim 13 which is an *Enterobacteriaceae* species.
15. A cell according to claim 1 where the gene coding for the adhesin protein is located on a plasmid.
16. A method of removing a metal compound from an environment, comprising adding to said environment a cell according to any of claims 1-15 which is capable of binding the metal compound to the second kind of binding domain, and separating the cell from the environment.
17. A method according to claim 16 wherein the cell is immobilized by binding to a receptor for the first kind of binding domain.

18. A population of recombinant cells, the population comprising a multiplicity of clones of a cell as defined in claim 1 each of which clones expresses an adhesin comprising a different second kind of binding domain.

5 19. A population according to claim 18 that comprises at least 10^6 different clones.

20. A method of constructing a cell population as defined in claim 18, comprising the steps of constructing a random library of DNA sequences coding for a peptide, inserting the library into a gene coding for an adhesin protein, and transforming a host
10 cell population with the library.

21. A method according to claim 20 wherein the adhesin is FimH.

22. A method according to claim 20 comprising a further step of enriching the cell
15 population for cells specifically binding to a particular compound to which the adhesin protein from which the multifunctional adhesin protein is derived, substantially does not bind, the step comprising contacting the cell population with said compound whereby cells expressing a second kind of binding domain that is capable of binding to the compound form aggregates with said compound, separating the cell-compound
20 aggregates and isolating cells capable of binding to the compound.

23. A method according to claim 22 wherein the compound is a metal compound.

24. A method according to claim 22 wherein the enrichment step is repeated two or
25 more times.

25. A method according to claim 22 wherein the first kind of binding domain is blocked during the enrichment procedure.

30 26. An isolated fimbrial structure comprising a multifunctional adhesin protein that contains at least one first kind of binding domain and at least one second kind of binding domain, said first kind of binding domain is capable of binding to an organic receptor and said second kind of binding domain is capable of binding to a compound to which the naturally occurring adhesin protein substantially does not bind.

27. A fimbrial structure according to claim 26 having a second kind of binding domain that binds to a metal.

- 5 28. Use of a cell according to any of claims 1-15 or a fimbrial structure according to claim 26 for removing a compound from an environment, the method comprising adding to the environment said cell or said fimbrial structure, which is capable of binding the compound to the second kind of binding domain and separating aggregates of cell or fimbrial structure with the compound from the environment.

10

29. Use according to claim 28 wherein the cell or the fimbrial structure are immobilized by binding to a receptor for the first kind of binding domain.

30. Use according to claim 28 wherein the compound being removed is a metal

15 compound.

31. Use of a cell according to any of claims 1-15 or a fimbrial structure according to claim 26 for removing a compound from an environment, the method comprising adding to the environment said cell or said fimbrial structure which is capable of

- 20 binding the compound to the first kind of binding domain and separating aggregates of cell or fimbrial structure with the compound from the environment.

32. Use according to claim 31 wherein the cell or the fimbrial structure are immobilized by binding to a receptor for the second kind of binding domain.



NOVEL MULTIFUNCTIONAL ADHESIN PROTEINS AND THEIR DISPLAY IN MICROBIAL CELLS

ABSTRACT

5

Recombinant cells expressing a multifunctional adhesin protein derived from a naturally occurring adhesin, containing a binding domain that is capable of binding to an organic receptor and a binding domain that is capable of binding to a compound to which the naturally occurring adhesin protein substantially does not bind. The cells or
10 modified adhesin proteins, optionally in immobilized form, are useful for separating organic and inorganic compounds including toxic or precious metals from an environment.

U.S. Pat. No. 5,840,000 (1999) is hereby incorporated by reference into this document.



<i>RS (H)₆RS</i>	pMAS25
<i>RS (H)₆RS (H)₆RS</i>	pNSU36
<i>RSARPRSASGPRSPM<u>H</u>TSTTPPRS</i>	pMAS38
<i>RSRT<u>H</u>GPGEGRPRS</i>	pMAS39
<i>RSSLSLFFRNRRSSVEDA<u>H</u>QTMRS</i>	pMAS40
<i>RSGANGREL<u>H</u>TRS</i>	pMAS41
<i>RSFSETAQSTGRSYVKFVWR<u>HH</u>RS</i>	pMAS42
<i>RSARG<u>H</u>VLISERS</i>	pMAS43
<i>RS<u>H</u>LSRLRGNRRS</i>	pMAS44
<i>RSRGVNDSPNGRSIT<u>H</u>IRRT<u>H</u>KRS</i>	pMAS45
<i>RSQVLRRPELIRSMPE<u>H</u>RRRE<u>H</u>RS</i>	pMAS46
<i>RSEERTGETGLRS<u>H</u>YGQLGYRRRS</i>	pMAS47
<i>RSLRNGILSR<u>H</u>RS</i>	pMAS48
<i>RSTVNGCVS<u>H</u>SRSGGLRASREVR</i>	pMAS49
<i>RSKVRLRDE<u>H</u>ERS</i>	pMAS50
<i>RSEGR<u>H</u>RRGGMRS</i>	pMAS51

Fig. 1




Fig. 2




Fig. 3




Fig. 4

5/8





Fig. 5






Fig. 6




Fig. 7




Fig. 8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of :)	
)	
Mark Andrew SCHEMBRI, <i>et al.</i>)	Group Art Unit: To Be Assigned
)	
Serial No.: To be Assigned)	Examiner: To Be Assigned
)	
Filed: Herewith)	

For: NOVEL MULTIFUNCTIONAL ADHESIN PROTEINS AND THEIR
DISPLAY IN MICROBIAL CELLS

**SUBMISSION OF SEQUENCE LISTING AND
STATEMENT UNDER 37 C.F.R. § 1.821**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the provisions of 37 C.F.R. § 1.821, Applicants submit herewith a paper copy of "Sequence Listing" corresponding to pages 32-43 of the above-identified application. Applicants request entry of the "Sequence Listing" into the record.

Applicants also submit herewith a computer readable copy of the "Sequence Listing" on a 3½ inch diskette, in ASCII format as required by 37 C.F.R. § 1.821(e).

The undersigned attorney, Stanislaus Aksman, hereby states that the content of the computer readable disk copy of the "Sequence Listing" and the attached paper copy of the "Sequence Listing" submitted herewith are the same. One formal change, not affecting the substance of the Sequence Listing, was made in the enclosed electronic

version and paper copy of the Sequence Listing, as compared to the Sequence Listing included in the application, i.e., the addition of a claim of priority from the provisional application. No impermissible new matter is introduced by the Sequence Listing.


To the extent necessary, the Commissioner is authorized to grant any extension of time deemed necessary for entry of this document and to charge additional fees associated with this communication or such extension of time or credit any overpayment to Deposit Account No. 50-0206. A duplicate copy of this communication is enclosed for accounting purposes.

Respectfully submitted,

HUNTON & WILLIAMS

Date: April 29, 1999

By:


Stanislaus Aksman
Registration No. 28,562

1900 K Street, N.W., Suite 1200
Washington, D.C. 20006-1109
Telephone: (202) 955-1500
Facsimile: (202) 778-2201

SEQUENCE LISTING

<110> Schembri, Mark Andrew
Klemm, Per

<120> Novel multifunctional adhesin proteins
and their display in microbial cells

<130> 21352 PC 1

<150> PA 1998 00598

<151> 1998-04-30

Prov PA 60/083,794

1998-05-01

<160> 46

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 300

<212> PRT

<213> E. coli PC31 FimH

<400> 1

```

Met Lys Arg Val Ile Thr Leu Phe Ala Val Leu Leu Met Gly Trp Ser
 1      5      10      15
Val Asn Ala Trp Ser Phe Ala Cys Lys Thr Ala Asn Gly Thr Ala Ile
 20     25     30
Pro Ile Gly Gly Gly Ser Ala Asn Val Tyr Val Asn Leu Ala Pro Val
 35     40     45
Val Asn Val Gly Gln Asn Leu Val Val Asp Leu Ser Thr Gln Ile Phe
 50     55     60
Cys His Asn Asp Tyr Pro Glu Thr Ile Thr Asp Tyr Val Thr Leu Gln
 65     70     75     80
Arg Gly Ser Ala Tyr Gly Gly Val Leu Ser Asn Phe Ser Gly Thr Val
 85     90     95
Lys Tyr Ser Gly Ser Ser Tyr Pro Phe Pro Thr Thr Ser Glu Thr Pro
100    105    110
Arg Val Val Tyr Asn Ser Arg Thr Asp Lys Pro Trp Pro Val Ala Leu
115    120    125
Tyr Leu Thr Pro Val Ser Ser Ala Gly Gly Val Ala Ile Lys Ala Gly
130    135    140

```


Ser Leu Ile Ala Val Leu Ile Leu Arg Gln Thr Asn Asn Tyr Asn Ser
 145 150 155 160
 Asp Asp Phe Gln Phe Val Trp Asn Ile Tyr Ala Asn Asn Asp Val Val
 165 170 175
 Val Pro Thr Gly Gly Cys Asp Val Ser Ala Arg Asp Val Thr Val Thr
 180 185 190
 Leu Pro Asp Tyr Pro Gly Ser Val Pro Ile Pro Leu Thr Val Tyr Cys
 195 200 205
 Ala Lys Ser Gln Asn Leu Gly Tyr Tyr Leu Ser Gly Thr His Ala Asp
 210 215 220
 Ala Gly Asn Ser Ile Phe Thr Asn Thr Ala Ser Phe Ser Pro Ala Gln
 225 230 235 240
 Gly Val Gly Val Gln Leu Thr Arg Asn Gly Thr Ile Ile Pro Ala Asn
 245 250 255
 Asn Thr Val Ser Leu Gly Ala Val Gly Thr Ser Ala Val Ser Leu Gly
 260 265 270
 Leu Thr Ala Asn Tyr Ala Arg Thr Gly Gly Gln Val Thr Ala Gly Asn
 275 280 285
 Val Gln Ser Ile Ile Gly Val Thr Phe Val Tyr Gln
 290 295 300

<210> 2

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Binding motif

<400> 2

His Xaa Xaa Xaa His Arg Ser
1 5

<210> 3

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Binding motif

<400> 3

Arg Xaa Xaa Xaa His Arg Ser

1 5

<210> 4

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Binding motif

<400> 4

Ser Lys Xaa Xaa His Arg Ser

1 5

<210> 5

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Binding motif

<400> 5

Ser Arg Xaa Xaa His Arg Ser

1 5

<210> 6

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Binding motif

<400> 6

Thr Lys Xaa Xaa His Arg Ser

1 5

<210> 7

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Binding motif

<400> 7

Thr Arg Xaa Xaa His Arg Ser

1 5

<210> 8

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide for the construction of a
double-stranded poly histidine segment (Example 1)

<400> 8

gatctcatca ccatcatcac catg

24

<210> 9

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide for the construction of a
double-stranded poly histidine segment (Example 1)

<400> 9

gatccatggt gatgatggtg atga

24

<210> 10

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> Template oligonucleotide

<400> 10

ggacgcagat ctvnnvnnvn nvnvnnvnn vnnvnnvnnna gatctagcac cagt

54

<210> 11

<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer oligonucleotide

<400> 11
actggtgcta gatct 15

<210> 12
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Sequence conferring the ability of cells to adhere
to metal oxides

<400> 12
Arg Ser Val Val Arg Pro Lys Ala Ala Thr Asn Arg Ser
1 5 10

<210> 13
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Sequence conferring the ability of cells to adhere
to metal oxides

<400> 13
Arg Ser Arg Ile Arg His Arg Leu Val Gly Gln Arg Ser
1 5 10

<210> 14
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> Sequence conferring the ability of cells to adhere

to metal oxides

<400> 14

Arg Ser Val Lys Asp Gly Ser Ala Thr Ala Lys Arg Ser Val Ala Asn

1 5 10 15

Phe Glu Thr Pro Arg Val Arg Ser

20

<210> 15

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to metal oxides

<400> 15

Arg Ser Ala Pro Gln Thr Gly Arg Pro Asn Asn Arg Ser Leu Pro Leu

1 5 10 15

Gly Asn Arg Asp Met Gln Arg Ser

20

<210> 16

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to metal oxides

<400> 16

Arg Ser Val Gln Asn Asp Arg Ile Val Ala Gly Arg Ser

1 5 10

<210> 17

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere

to metal oxides

<400> 17

Arg Ser Tyr Pro Pro Phe His Asn Asn Asp His Arg Ser
1 5 10

<210> 18

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to metal oxides

<400> 18

Arg Ser Asn Thr Arg Met Thr Ala Arg Gln His Arg Ser Ala Asn His
1 5 10 15
Lys Ser Thr Gln Arg Ala Arg Ser
20

<210> 19

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to metal oxides

<400> 19

Arg Ser Leu Ala Ile Asp Gly Thr Asp Val Gln Arg Ser Lys Pro Leu
1 5 10 15
Ala Arg Ser Ser Gly Ala Arg Ser
20

<210> 20

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere

to metal oxides

<400> 20

Arg Ser Pro Ser Pro Ile Arg Val Pro His His Arg Ser Thr Ala Ile
1 5 10 15
Pro Asn Arg Gln Leu Ile Arg Ser Gln Ile Arg Ile His Ala Met Gly
20 25 30
His Arg Ser
35

<210> 21

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to metal oxides

<400> 21

Arg Ser Arg Arg Val Arg Asp Ile His Leu Gly Arg Ser Val Gln His
1 5 10 15
Arg Leu Gly Gln Pro Leu Arg Ser Leu His Gln Gln Ser Ser Pro Thr
20 25 30
Leu Arg Ser
35

<210> 22

<211> 46

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to metal oxides

<400> 22

Arg Ser Arg Thr Pro Leu Ala Pro Val Pro Val Arg Ser Trp His Ile
1 5 10 15
Gly Ser Arg Thr Ile Ala Arg Ser Phe Asn Gly Ile Thr Ile Gly Asp
20 25 30
Asn Arg Ser Tyr Ile Pro Glu His Trp Tyr Trp Ser Arg Ser
35 40 45

<210> 23

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to metal oxides

<400> 23

Arg Ser Gly Arg Met Gln Arg Arg Val Ala His Arg Ser
1 5 10

<210> 24

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to metal oxides

<400> 24

Arg Ser Leu Gly Lys Asp Arg Pro His Phe His Arg Ser
1 5 10

<210> 25

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to metal oxides

<400> 25

Arg Ser Arg Gly Leu Arg Asn Ile Leu Met Leu Arg Ser Tyr Asp Ser
1 5 10 15
Arg Ser Met Arg Pro His Arg Ser
20

<210> 26

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to metal oxides

<400> 26

Arg Ser Glu Pro Arg Arg Ala Thr Gln Ala Pro Arg Ser Lys Pro Gln
1 5 10 15
Lys Asn Glu Pro Ala Pro Arg Ser
20

<210> 27

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to metal oxides

<400> 27

Arg Ser Leu Gly Ala Val Ser Ser Leu Phe Ser Arg Ser Gln Lys Ile
1 5 10 15
Met Gln Thr Asp Ile Val Arg Ser Lys Gly Val Arg Pro Gly Ala Gln
20 25 30
Arg Arg Ser
35

<210> 28

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to metal oxides

<400> 28

Arg Ser His His Met Leu Arg Arg Arg Asn Thr Arg Ser
1 5 10

<210> 29

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to metal oxides

<400> 29

Arg Ser His Ile Asn Ala Ser Gln Arg Val Ala Arg Ser
1 5 10

<210> 30

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to metal oxides

<400> 30

Arg Ser Cys Pro Arg Leu Gly Val Trp Phe Tyr Arg Ser Leu Ser Val
1 5 10 15
Gly Asp Gly Phe Val Arg Arg Ser
20

<210> 31

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to metal oxides

<400> 31

Arg Ser Thr Ser Gly Pro Ser Arg Val Met Thr Arg Ser Ile Ile Leu
1 5 10 15
Arg Ile Gly Thr Leu Asp Arg Ser Cys Leu Lys Val Phe His Met Gly
20 25 30

Trp Arg Ser
35

<210> 32

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to metal oxides

<400> 32

Arg Ser Ile Thr Pro Ile Leu His Asp His Arg Arg Ser Ser Val Arg

1 5 10 15

Pro Met Val Ala His Arg Arg Ser Pro Thr Leu Tyr Phe Pro Ala Ala

20 25 30

Ser Arg Ser

35

<210> 33

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Binding motif

<400> 33

Ser Lys Xaa Xaa Ala Arg

1 5

<210> 34

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Binding motif

<400> 34

Ser Arg Xaa Xaa Ala Arg

1 5

<210> 35
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Binding motif

<400> 35
Thr Lys Xaa Xaa Ala Arg
1 5

<210> 36
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Binding motif

<400> 36
Thr Arg Xaa Xaa Ala Arg
1 5

<210> 37
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Binding motif

<400> 37
Arg Xaa Xaa Xaa His Arg Ser
1 5

<210> 38
<211> 24
<212> PRT
<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to ZnO

<400> 38

Arg Ser Asn Thr Arg Met Thr Ala Arg Gln His Arg Ser Ala Asn His
1 5 10 15
Lys Ser Thr Gln Arg Ala Arg Ser
20

<210> 39

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to ZnO

<400> 39

Arg Ser Val Phe Leu Pro Ser Ile Leu Gly Trp Arg Ser Arg Leu Asp
1 5 10 15
Asp Gln Gly Val Ala Ala Arg Ser
20

<210> 40

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to ZnO

<400> 40

Arg Ser Thr Arg Asn Lys His Thr Thr Ala Arg Arg Ser Val Ala Pro
1 5 10 15
Gly Ile Gly Glu Pro Ser Arg Ser
20

<210> 41

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to ZnO

<400> 41

Arg Ser Ile Met His Val Arg Leu Arg Ala Arg Arg Ser Ala Arg His
1 5 10 15
Met Lys Asp Ala Asp Pro Arg Ser
20

<210> 42

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to ZnO

<400> 42

Arg Ser Pro Ile Ile Arg Ser Arg Ile Asn Arg Ser His Gly Arg
1 5 10 15
Thr Lys Ala Thr Pro Ala Arg Ser
20

<210> 43

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to ZnO

<400> 43

Arg Ser Arg Gly Leu Arg Asn Ile Leu Met Leu Arg Ser Tyr Asp Ser
1 5 10 15
Arg Ser Met Arg Pro His Arg Ser
20

<210> 44

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to ZnO

<400> 44

Arg Ser Thr Arg Arg Gly Thr His Asn Lys Asp Arg Ser
1 5 10

<210> 45

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to ZnO

<400> 45

Arg Ser Thr Val Pro Lys Lys Arg His Pro Lys Asp Arg Ser
1 5 10

<210> 46

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence conferring the ability of cells to adhere
to ZnO

<400> 46

Arg Ser Tyr Asp Ser Arg Ser Met Arg Pro His Arg Ser
1 5 10